ALSO IN THIS MONTH'S ISSUE
What’s Next In Biotech’s Deal Playbook?
Facing deflated investor confidence, precipitously low stock market runs, rising interest rates, and commercial setbacks, underperforming biotech companies and their boards need to be resourceful to stay afloat. The right deal-making strategy can drive the business forward.
What To Consider When Acquiring A Biopharma Manufacturing Facility
In this article, I share the considerations you should keep in mind when acquiring a stand-alone biopharma manufacturing facility, using a real-life example from my experience.
Biopharma In China: The Emerging Global Force Of Domestic Suppliers
A major factor in the emerging domestic competition is the Chinese drug industry’s response to cost pressures being implemented, such as the volume-based procurement (VBP) policy.
How Cell And Gene Therapies Are Advancing Collaborations In Biopharma
The last time I wrote for Life Science Leader, I highlighted the importance of collaboration in the field of regenerative medicine. Here, I wanted to reassess how these collaborations are elevating the state of science as well as diversity initiatives with a focus on cell and gene therapies.
BEYOND THE PRINTED PAGE
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.